Vaxcyte Inc. (PCVX)
Summary
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 75.6% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027
Vaxcyte remains a 'Strong Buy' after robust phase 3 OPUS-1 results for VAX-31, demonstrating non-inferiority to Prevnar 20 and Capvaxive in adults. The company offers significant upside with multiple 2027 catalysts: OPUS-2 and OPUS-3 phase 3 data for VAX-31 in adults in the 1st half of 2027 and phase 2 infant data. VAX-31 targets broader pneumococcal strain coverage versus current vaccines, addressing emerging serotypes and aiming for 95% adult IPD coverage.
Vaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial
Vaxcyte NASDAQ: PCVX said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults.
Vaxcyte Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 238 | $10,064.21 | $14,601.89 | $4,537.68 | 45.09% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 200 | $9,228 | $11,934.08 | $2,706.08 | 29.32% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 22 | $971.42 | $1,348.7 | $377.28 | 38.84% |
| RW Riley Wancket HANTZ FINANCIAL SERVICES Inc. | 26 | $1,283.43 | $1,556.88 | $273.45 | 21.31% |
| BG Bart Gancher Intech Investment Management LLC | 28,577 | $1.13M | $1.83M | $699,160.98 | 61.78% |
Vaxcyte Inc. (PCVX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vaxcyte Inc. ever had a stock split?
Vaxcyte Inc. Profile
| Biotechnology Industry | Healthcare Sector | Grant E. Pickering CEO | NASDAQ (NGS) Exchange | 92243G108 CUSIP |
| US Country | 507 Employees | - Last Dividend | - Last Split | 12 Jun 2020 IPO Date |
Overview
Vaxcyte, Inc. represents a pioneering force in the field of biotechnology, focusing its considerable expertise on the development of innovative protein vaccines aimed at the prevention and treatment of bacterial infectious diseases. Born from its previous incarnation as SutroVax, Inc., the company underwent a rebranding in May 2020 to emerge as Vaxcyte, Inc., marking a new chapter in its commitment to combatting infectious diseases. Since its establishment in 2013, Vaxcyte has dedicated itself to advancing science and technology with its headquarters located in San Carlos, California. The company's approach blends cutting-edge research with clinical acumen, underscoring its ambition to address some of the most challenging bacterial pathogens through its vaccine development pipeline.
Products and Services
- VAX-24:
As Vaxcyte, Inc.'s frontrunner candidate, VAX-24 is a 24-valent investigational pneumococcal conjugate vaccine designed with the vision of preventing invasive pneumococcal disease. This vaccine exemplifies the company's dedication to innovation in vaccine technology, targeting a wide range of pneumococcal strains to offer comprehensive protection.
- VAX-31:
VAX-31 is a testament to Vaxcyte’s forward-thinking strategy, aiming to provide immunity against emerging bacterial strains and the ever-growing challenge of antibiotic resistance. This vaccine candidate is designed to extend the protective reach beyond the current vaccine offerings and address future public health needs.
- VAX-A1:
Focusing on the causative agent of severe throat infections, VAX-A1 is a novel conjugate vaccine candidate targeting Group A Streptococcus. VAX-A1 represents Vaxcyte's ambition to prevent diseases caused by this common, yet potentially dangerous, bacterium.
- VAX-PG:
Vaxcyte's innovative approach to oral health is embodied in VAX-PG, a novel protein vaccine candidate aimed at combating the keystone pathogen responsible for periodontitis. This vaccine underlines the company's commitment to expanding the scope of vaccine-preventable diseases to include oral health conditions.
- VAX-GI:
Addressing the need for vaccines against gastrointestinal infections, VAX-GI is being developed to prevent disease caused by Shigella, a bacterium responsible for significant illness globally. This vaccine candidate highlights Vaxcyte's efforts to tackle a broad spectrum of infectious agents through its diversified vaccine pipeline.
Contact Information
